Figure 2 | Scientific Reports

Figure 2

From: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Figure 2

Analysis of cell cycle changes and apoptosis after LB100 treatment. (A,B) Flow cytometry analysis was performed to determine the relative percentage of SKM-1 cells in various phases of the cell cycle after 5 μM LB100 treatment for 0, 6 and 12 h. Quantification of data demonstrates a time-dependent shift towards G2/M phase. (C) SKM-1 cells displayed a time-dependent decrease in G2/M regulatory proteins after 5 μM LB100 treatment. (D) Flow cytometry analysis of SKM-1 cells stained with annexin V and propidium iodide demonstrated LB100 induced apoptosis in a concentration-dependent manner. (E) SKM-1 cells displayed a dose dependent increase in cleaved caspase 3 and PARP after 24 h exposure to LB100. (F) Fluorescent microscopy of Hoechst-stained SKM-1 cells demonstrated an increased amount of condensed and/or fragmented nuclei after progressively high doses of LB100. (G) Flow cytometry analysis was performed to quantify the proportion of apoptotic cells after 24 h of LB100 treatment (10 μM) or control, in the presence or absence of z-VAD-FMK. z-VAD-FMK rescued cells from LB100-induced cell death, demonstrating a caspase-dependent mechanism of LB100-mediated cytotoxicity. Statistically significant differences are marked by an asterisk (*P < 0.05; **P < 0.01, ***P ≤ 0.001).

Back to article page